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Summary
Metastases to the female genital tract from extra-genital primary cancers are uncommon and usually occur during 
widespread metastatic disease. Breast cancers are the most frequent primaries, predominantly the lobular type. Here, we 
report a case of a 55-year-old woman with breast cancer endometrial metastasis who presented with postmenopausal vagi-
nal bleeding. We highlight the importance of endometrial sampling to confirm the diagnosis and distinguish primary from 
metastatic cancer of the endometrium since the treatment and prognosis of these conditions are entirely different.
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Breast cancer is the most common malignan-
cy in women worldwide (1). Approximately 6% of 
breast cancer patients initially present with metas-
tases, and 30% will develop metastasis after de-
finitive treatment (2). The most often breast cancer 
metastasis sites are lung, liver, bone, and brain, 
while primary metastases to the female genital 
tract are extremely rare (3,4). When metastases to 
the genital tract are present, ovaries are the most 
often involved due to peritoneal spread, account-
ing for 75.8% of metastasis to genital organs (2). 
Breast cancer metastasis to the uterus is an exceed-
ingly rare clinical finding and presents a signifi-
cant diagnostic challenge (2,5). Herein, we report 
a case of a breast cancer patient who presented 
with abnormal uterine bleeding and was subse-
quently diagnosed with breast cancer metastasis 
to the endometrium.
CASE REPORT
A 55-year-old woman presented to her pri-
mary gynecologist with postmenopausal vaginal 
bleeding. She was diagnosed with breast cancer 
two years ago and underwent a segmental mas-
tectomy with sentinel lymph node dissection. Pa-
thology revealed grade 3 invasive lobular car-
cinoma measuring 2.2 cm, ER/PR+, and Her-2 
negative, Ki-67 was 26.2%. Epithelial cadherin 
(E-cad herin) had an aberrant expression. Micro-
scopic examination of sentinel lymph nodes came 
positive for metastasis. After surgery, she received 
adjuvant chemotherapy (4 cycles of cyclophos-
phamide and adriamycin followed by 12 cycles of 
paclitaxel) and radiation therapy (total dose of 50 
Gy/25 fractions followed by a boost dose of 12.5 
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Gy/5 fractions). Since the tumor showed strongly 
positive hormone receptor expression, she was 
under endocrine therapy with anastrozole.
Approximately two years after her initial di-
agnosis, the patient experienced postmenopausal 
uterine bleeding. Vaginal bleeding was mild and 
self-limited, while speculum examination did not 
reveal any signs of vaginal bleeding. Due to post-
menopausal vaginal bleeding, an endometrial bi-
opsy was performed. Histopathology with immu-
nohistochemical staining confirmed metastases to 
the endometrium, consistent with her known his-
tory of invasive lobular breast carcinoma. She was 
referred to our department for evaluation and fur-
ther management. PET/CT scan was administered 
and did not reveal areas of increased uptake in 
either the ovaries or the uterus. However, the pa-
tient had diffuse osseous metastases. During a 
multidisciplinary team conference, the patient 
was discussed and decided to undergo systemic 
therapy with pablociclib and fulvestrant due to 
hormone-receptor-positive advanced breast can-
cer, which has progressed on prior endocrine 
 therapy. The patient is under the sixth cycle of 
therapy without disease progression signs on 
PET/CT scan.
DISCUSSION
Metastases from extra-genital cancers to the 
genital tract are extremely rare, with breast and 
colon being the most common origins of metasta-
ses (5,6). Piura et al. concluded that 56% of pri-
mary extra-genital cancers that metastasize to the 
uterus originate from the breast. However, when 
the genital tract is affected, the ovaries are the 
most common site of metastases (5,7). One study 
reported that, among 149 metastatic tumors to the 
female genital tract from extra-genital cancers, the 
ovary and vagina were the most frequent metasta-
ses (75.8% and 13.4%), and only 8.1% were to the 
uterus (8). Mazur et al. analyzed the localization 
of the metastases in the uterus: 3.8% of cases in-
volved the endometrium, 63,5% of cases involved 
myometrium, and 32.7% of cases both the myome-
trium and endometrium(9).
Although rarer than ductal type, invasive 
lobular cancer is the most frequent histologic type 
that metastasizes the female genital tract. These 
differences between infiltrating lobular carcinoma 
and ductal carcinoma could be because of the 
small size of lobular cancer cells and loss of cell 
adhesion molecule E-cadherin expression (3,10). 
E-cadherin is a transmembrane glycoprotein that 
mediates intercellular adhesion and is engaged in 
epithelial cell-to-cell adhesion. Numerous studies 
have linked aberrant expression of E-cadherin, as 
in our case report, with more invasive cancer phe-
notype and the development of metastases in 
breast cancer and other cancers (11).
Uterine metastases of extra-genital cancer 
pose a significant diagnostic challenge for both 
physicians and pathologists. It may be challenging 
to differentiate between uterine cancer and the 
uterine metastases of breast cancer. Both have simi-
lar glandular architecture, and both, in most cases, 
demonstrate hormone receptors’ positivity. GATA3 
and cytokeratin immunohistochemical staining 
should be used in such cases since they are sensi-
tive markers for metastatic breast cancer (2,12).
Abnormal uterine bleeding is often the first 
symptom when the endometrium is involved. 
However, if the metastases affect myometrium 
only, patients may often be asymptomatic (6,10). It 
is easy to mistake the typical presentation of ab-
normal vaginal bleeding as a primary disease 
rather than the genital tract’s metastatic involve-
ment. Endometrial biopsy is crucial in distinguish-
ing primary from metastatic cancer of the endo-
metrium (4,5). Uterine metastases from extra-gen-
ital cancers usually occur as a manifestation of 
advanced disease, and in the majority of cases, 
ovaries are also affected (5,13). However, in our 
case, both ultrasound and PET/CT scans of ovaries 
were normal.
There is a lack of data regarding the best ap-
proach in uterine metastases in the context of 
widespread disease. Most studies suggest no fore-
seeable benefit from specific local treatment (e.g., 
surgery or radiotherapy) other than palliation of 
symptoms and prevention of cancer-related com-
plications (5,14). Systemic therapy is considered to 
be the mainstay of the treatment of such patients 
(5,14,15).
CONCLUSION
In conclusion, this case report shows how im-
portant it is to maintain a broad differential diag-
nosis in patients with postmenopausal bleeding 
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and breast cancer history. It is of utmost impor-
tance to determine whether the uterine tumor is 
metastatic or primary since treatment modalities 
and prognosis of these conditions are entirely dif-
ferent. Proper evaluation of symptoms with an en-
dometrial biopsy is essential in identifying the un-
derlying pathology. However, due to data paucity 
regarding this condition, more cases and more 
studies are necessary to improve our knowledge 
about the best treatment options for these patients.
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Sažetak
RIJEDAK SLUČAJ METASTAZE INVAZIVNOG LOBULARNOG KARCINOMA DOJKE U ENDOMETRIJ
D. Danolić, L. Marcelić, I. Alvir, I. Mamić, L. Šušnjar, Z. Rendić-Miočević i M. Puljiz
Metastaze u ženski spolni sustav ekstragenitalnih primarnih karcinoma su rijetke te su najčešće znak uznapredovale 
bolesti. Lobularni histološki tip karcinoma dojke je najčešće primarno sijelo metastaza u ženski spolni sustav. U radu je 
prikazan rijedak slučaj 55- godišnje bolesnice s endometralnom metastazom karcinoma dojke koja se prvotno prezentirala 
sa simptomima vaginalnog krvarenja u poslijemenopauzi. Istaknuta je važnost biopsije endometrija u postavljanju točne 
dijagnoze i razlikovanju primarne od metastatske bolesti endometrija s obzirom na činjenicu kako se njihovo liječenje i pro-
gnoza u potpunosti razlikuju.
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